This is an Open Label Extension Study (OLES) for patients who participated in the 18 month
double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study)
studying the effect of ALX1-11, recombinant human parathyroid hormone, rhPTH(1-84), on
vertebral fracture incidence. The primary objective of this study is to evaluate the safety
of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal
osteoporotic women who participated in Protocol ALX1 11 93001.